DNA methylation based FDA-approved LB assays for CRC early detection are Epi proColon® (Epigenomics AG, Berlin, Germany) and RealTime mS9 CRC Assay (Abbott Laboratories Chicago, IL, USA) to detect SEPT9 promoter methylation, and Cologuard® (Exact Sciences Co., Madison, WI, USA) targeting changes in methylation of BMP3 and NDRG4 promoters and seven KRAS gene point mutations [45]. The gene discussed is BMP3; the disease is colorectal carcinoma.